Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers

Squamous Cell Carcinoma of Anal Canal Clinical Trial

Official title:
A Phase II Clinical Study Using Nimotuzumab in Combination With External Beam Radiation Therapy in the Treatment of Patients With Carcinomas of the Anal Canal

Status Terminated

Clinical Trial Summary

The objective of this study is to demonstrate the feasibility of using Nimotuzumab and radiation in the treatment of squamous cell carcinomas of the anal canal in order to achieve a 65% local control rate with a better toxicity profile than the conventional treatment. Patients with high toxicity risks (HIV+ and fragile patients) will be selected for this study.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Anus Neoplasms
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Anal Canal

Clinical Trial Details

NCT number	NCT01382745
Study type	Interventional
Source	Sir Mortimer B. Davis - Jewish General Hospital
Contact
Status	Terminated
Phase	Phase 2
Start date	January 2012
Completion date	January 2022

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03597295` - A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)	Phase 2
	Recruiting	`NCT04429542` - Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors	Phase 1